

KRYZA David

### Degree

- Pharm D, Faculty of Pharmacy, 2005, LYON
- "DESC de radiopharmacie et radiobiologie", 2006, Saclay
- PhD, Claude Bernard Lyon I University, Lyon (Specialty: Radiochemistry and radiopharmacy) defended on November 2007 (thesis experiments performed at Advanced Accelerator Applications (AAA, St Genis Pouilly))
- "Habilitation à diriger les recherches" (HDR) defended on February 2015

### POSITION & MAIN DOMAIN OF RESEARCH

Assistant professor at ISPB (Faculté de Pharmacie de Lyon) -Claude Bernard Lyon 1 University and Head of the radiopharmacy unit at Nuclear medicine center LUMEN (Hospices Civils de Lyon – Centre Léon Bérard)

Leader of the small animal preclinical imaging platform IMTHERNAT

Member of LAGEPP (UCBL1-UMR CNRS 5007-CPE)

Member of the administration committee and the bureau of the French Society of Nuclear Medicine (SFMN)

### OUTPUT

D Kryza published 46 research articles, 7 patents and 1 book chapter (H index 15, SIGAPS 677). He supervised 5 PhD students, 3 post-doctoral students and 7 M2 students.

D Kryza participated to 15 ANR, INCa or European projects. In particular, he was the co-leader of the SPEDIV project (2016-2019) funded by AVIESAN/INCA/INSERM, dedicated to in-vivo image-based quantification of NPs for enhanced radiotherapy treatment and actively involved in the ANR "Chondrad" (2014-2018). He was although leader of the 2 projects funded by "Cancéropole Auvergne Rhone Alpes" (2016 and 2019). He is the leader of the Interest Project funded by INCa-PRTK-2020.

D Kryza has participated to > 40 clinical trials from phase I to phase III using diagnostic or therapeutic radiopharmaceuticals in the Lumen nuclear medicine unit (Centre Léon Bérard -Hospices civils de Lyon).

### TEACHING ACTIVITIES & OTHER RELEVANT INFO

2008-present Lecturer "radiopharmacy", 3rd Bachelor Pharmaceutical Sciences and Master students

2021-current: Associated Editor Frontiers in nuclear medicine (IF 4.4).

2015-current: Elected member of the administrative council of the faculty of pharmacy, Lyon

2021-current : Elected member of the administrative council of LAGEPP

2013-current Elected Member of Conseil National des Universités (section 80)

Winner of the Internship Gold Medal Competition "Lauréat du concours de la médaille d'or de l'internat", 2006

### 10 LAST PUBLICATIONS

- Pretet V, Moreau A, Larrouquere L, Mognetti T, **Kryza D**. A False-Positive Bone Oligometastatic Prostate Cancer in 18F-Choline PET/CT: Be Aware of Chronic Vascular Pitfalls. Clin Nucl Med. 2023 Sep 29. doi: 10.1097/RLU.0000000000004883.
- Vergnaud L, Badel JN, Giraudet AL, **Kryza D**, Mognetti T, Baudier T, Rida H, Dieudonné A, Sarrut D. Performance study of a 360° CZT camera for monitoring <sup>177</sup>Lu-PSMA treatment. EJNMMI Phys. 2023 Sep 22;10(1):58. doi: 10.1186/s40658-023-00576-1.
- Andretto V, Dusi S, Zilio S, Repellin M, **Kryza D**, Ugel S, Lollo G. Tackling TNF- $\alpha$  in autoinflammatory disorders and autoimmune diseases: From conventional to cutting

Docteur David KRYZA  
LUMEN  
15 rue Gabriel Sarrazin  
69373 LYON Cedex 08  
N° RPPS 1000002218  
N° FINES (GCS/LU) 69 003 730 4  
Tel. 04 78 78 26 83

6/6/23

- edge in biologics and RNA- based nanomedicines. *Adv Drug Deliv Rev.* 2023 Oct;201:115080. doi: 10.1016/j.addr.2023.115080.
- Giraudet AL, Vinceneux A, Pretet V, Paquet E, Lajusticia AS, Khayi F, Badel JN, Boyle H, Flechon A, **Kryza D**. Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma. *Pharmaceuticals (Basel).* 2023 Jul 12;16(7):995. doi: 10.3390/ph16070995.
  - Breusa S, Zilio S, Catania G, Bakrin N, **Kryza D**, Lollo G. Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. *Front Oncol.* 2023 May 23;13:1125868. doi: 10.3389/fonc.2023.1125868.
  - Moreau A, Khayi F, Maureille A, Bonneville-Levard A, Larrouquere L, Ducray F, **Kryza D**. Discriminating Inflammatory Radiation-Related Changes From Early Recurrence in Patients With Glioblastomas: A Preliminary Analysis of 68 Ga-PSMA-11 PET/CT Compared With 18 F-FDOPA PET/CT. *Clin Nucl Med.* 2023 Aug 1;48(8):657-666. doi: 10.1097/RLU.0000000000004716.
  - Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, **Kryza D**, Evesque A, Jordheim LP, Perrial E, Matera EL, Caroff M, Kerzerho J, Dumontet C. A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models. *Front Immunol.* 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402.
  - **Kryza D**, Wischhusen J, Richaud M, Hervieu M, Sidi Boumedine J, Delcros JG, Besse S, Baudier T, Laval PA, Breusa S, Boutault E, Clermidy H, Rama N, Ducarouge B, Devouassoux-Shisheboran M, Chezal JM, Giraudet AL, Walter T, Mehlen P, Sarrut D, Gibert B. From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors. *EMBO Mol Med.* 2023 Apr 11;15(4):e16732. doi: 10.15252/emmm.202216732.
  - **Kryza D**, Moreau A, Badel JN, Mognetti T, Giraudet AL. Unintentional Intra-arterial Injection of <sup>177</sup>Lu-PSMA-1 in a Patient With a Peritoneal Carcinosis Secondary to a Metastatic Prostate Cancer. *Clin Nucl Med.* 2023 Feb 1;48(2):203-205. doi: 10.1097/RLU.0000000000004492. Epub 2022 Nov 18.
  - Andretto V, Repellin M, Pujol M, Almouazen E, Sidi-Boumedine J, Granjon T, Zhang H, Remaut K, Jordheim LP, Briançon S, Keil IS, Vascotto F, Walzer KC, Sahin U, Haas H, **Kryza D**, Lollo G. Hybrid core-shell particles for mRNA systemic delivery. *J Control Release.* 2023 Jan;353:1037-1049. doi: 10.1016/j.jconrel.2022.11.042.